(Q33411190)

26 July 2017

title

Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib (English)

1 reference

26 July 2017

1 reference

hepatocellular carcinoma

1 reference

4

Hajime Sunagozaka

1 reference

26 July 2017

Takeshi Terashima

1

1 reference

26 July 2017

Tatsuya Yamashita

2

1 reference

26 July 2017

Kuniaki Arai

3

1 reference

26 July 2017

Masaaki Kitahara

5

1 reference

26 July 2017

Hidetoshi Nakagawa

6

1 reference

26 July 2017

Takashi Kagaya

7

1 reference

26 July 2017

Eishiro Mizukoshi

8

1 reference

26 July 2017

Masao Honda

9

1 reference

26 July 2017

Shuichi Kaneko

10

1 reference

26 July 2017

publication date

8 January 2014

1 reference

26 July 2017

1 reference

26 July 2017

volume

44

1 reference

26 July 2017

issue

12

1 reference

26 July 2017

page(s)

1179-1185

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Diagnosis of hepatocellular carcinoma: newer radiological tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: Ten-year results of 124 patients in a prospective protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12266

21 January 2018

Identifiers

DOI

10.1111/HEPR.12266

1 reference

release_sxeejkg6a5egxft7xfnnmtsfri

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sxeejkg6a5egxft7xfnnmtsfri

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference